RxDoctor Payments Data

Judith Lightfoot, DO

Infectious Disease · Stratford, NJNPI 1922046630

Payments from drug & device makers

$331in general payments, 2019–2025

Across 14 payments — averaging $23.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GRT US Holding, Inc.$186
  • Viiv Healthcare Company$100
  • Novo Nordisk$16
  • Gilead$15
  • Johnson & Johnson$13

What the payments were for

  • Food & beverage$14544%
  • Education$18656%

General payments by program year

19
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$331 in reported general payments places this provider in the 35th percentile of 334 infectious disease providers in New Jersey.

See all infectious disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$2,320,444
Medicare patients
167
Services billed
48,295

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala210$835,623
GenvoyaElviteg/Cob/Emtri/Tenof Alafen183$728,736
TriumeqAbacavir/Dolutegravir/Lamivudi156$606,658
JulucaDolutegravir/Rilpivirine63$215,823
CabenuvaCabotegravir/Rilpivirine28$192,302
StribildElviteg/Cob/Emtri/Tenofo Disop44$173,741
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5015$141,630
DovatoDolutegravir Sodium/Lamivudine41$120,549
OdefseyEmtricitab/Rilpiviri/Tenof Ala30$105,133
DescovyEmtricitabine/Tenofov Alafenam47$101,302
TivicayDolutegravir Sodium47$101,026
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf18$89,905
EdurantRilpivirine Hcl18$35,477
OzempicSemaglutide36$33,066
Isentress HdRaltegravir Potassium17$32,706

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Stribild, Descovy$15$1,839,403484 claims
Viiv Healthcare CompanyTriumeq, Juluca, Cabenuva, Dovato, Tivicay$100$1,236,358335 claims
Novo NordiskOzempic$16$33,06636 claims
Johnson & JohnsonXarelto$13$19,82237 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 334 infectious disease providers in New Jersey.

Other infectious disease in Stratford

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →